Pharmaceutical Executive, Mar 1, 2006 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Mar 1, 2006
Features
Pharma's Next Top Model: Slimmer Business Models
By Jerry Cacciotti , Bill Shew
The disease profiles pharma companies pursue should shape the business models that enable them to grow.
Holding Their Breath: Inhaled Insulin
By Ron Feemster
All of the companies with inhaled-insulin drugs must perform two-year safety studies. Not because their drugs show troubling data, but because Exubera has caused slight, temporary decreases in lung function.
Invisible Prescribers: What You Do and Don't Know About NPs and PAs
By Sharyn Lee
Before a pharmaceutical company dispatches a sales rep to a medical practice, the marketing department learns some basic facts about the physician: how many new prescriptions she's written, how many refills, and how much upside prescribing growth she might generate. What the rep usually doesn't know: who else—nurse practitioners and physician assistants—prescribes medications in the office, at a nearby clinic, or sometimes in a separate practice just down the hall.
Columns
Alternative Media: Masters of Their Domain
By Alana Klein
For years, educational institutions have enjoyed their own Internet domain: .edu. US governmental agencies have .gov, and non-profits have been able to set themselves apart from the crowd with .org in their e-mail and Web addresses. Thanks to changes made to the Internet's Domain Name System (DNS) in 2001, subject-specific vertical segments have been able to flee the .com world for newly established domains, such as .travel, .jobs, .museum, and .info.
Backpage: Warning Letter
By Lou Morris
This letter concerns the FDA press release dated January 18, 2006, entitled "FDA Announces New Prescription Drug Information Format to Improve Patient Safety." The information contained is considered false and misleading, and lacking in fair balance.
Sales Management: Spending Under Scrutiny
By Jeff Brady
Given the high volume of rep interactions with healthcare professionals, companies must work toward achieving a fully integrated system that collects data from across the entire enterprise.
Marketing to Professionals: Under the Influence
By Susan Dorfman , Jerry Maynor
Marketers should target doctors who exhibit a high level of influence and connectivity among prescribers within and outside their specialities. Often, doctors' influence can extend to general practitioners, too.
Direct to Consumer: Q&A with Jill Balderson
By Alana Klein
We need to do more than just distribute information—we need to look at how consumers process, internalize, and act on that information. Health education is a process that is very personal and complex.
Washington Report
Washington Report: Labels and Liability
By Jill Wechsler
Pharmaceutical companies are worried that FDA's new labeling format will expose them to liability suits from individuals who suffer adverse events that are not highlighted, but "hidden" in the full prescribing information.
From the Editor
From the Editor: Fine Whines
By Patrick Clinton
The newspapers seem shocked to learn that scientific journals occasionally publish things that aren't true. Where have they been?
Special Reports
Market Research Roundtable
By Joanna Breitstein , Patrick Clinton
Understanding how drugs are bought and paid for has always been a bit complicated. People used to say that pharma had two customers—physicians and patients. Only one of them used the drug, and neither of them knew the price. My, how times have changed. Now the industry has so many customers, it needs to stop and get to know them all over again. And that's at a time when drugs worth tens of billions of dollars are going off patent. To map pharma's shifting landscape, Pharm Exec convened a group of top market researchers to discuss the issues shaping an evolving industry. Topics ranged far and wide, from the advent of Medicare Part D, to the new focus on adherence, the role of international markets, even the brave new world of marketing to seniors' children.
Company Profile
Genzyme: The Price of Success
By Sara Calabro
Genzyme has an impressive international record in regions with intact healthcare systems. but so far, algeria is one of very few countries where genzyme's drugs have gone from free to paid for. the company is basing a huge investment on faith.
Global Report
Global Report: Chemicals Legislation in Europe
By Sarah Houlton
Drugs are not directly addressed in Europe's new legislation for chemicals. But they'll be affected, because chemicals are used in drug manufacturing.
Thought Leader
Thought Leader: Q&A with Hugo Stephenson
By Joanna Breitstein
Companies don't have the budget, but are being forced to do more active surveillance.
Leadership
Finance: Promotional Productivity
By Blair Gibson
Lovenox still needs a defense strategy to hold share, but it requires less investment as a specialty product. Instead, Lovenox should throw cash over to Acomplia, the putative future star of the Sanofi-Aventis portfolio.
Legal
Legal: Hey, Good Lookin': Sex Discrimination in Hiring Reps
By James McDonald, Jr.
Drug manufacturers should have policies against sexual harassment of sales reps. Such a policy may also help counter charges that a company is implicitly encouraging its reps to use their sexuality as a sales tool.

ADVERTISEMENT

Click here